SCHEMBL10112499

SCHEMBL10112499

COC(=O)c1cccc(-c2c3ccccc3c(-c3cccc(C(=O)OC)c3)c3c(N(c4ccccc4)c4ccc5c(c4)c4ccccc4n5-c4ccccc4)cccc23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PMM2 O15305 1/20 0.37
MPI P34949 1/20 0.37
RAB9A P51151 1/20 0.37
PHOSPHO1 Q8TCT1 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
PTGER4 P35408 2/20 0.36
MAPK8 P45983 1/20 0.36
TP53 P04637 3/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112620 0.95 KDM4E (0.38) KDM4EMAPTCYP1A2CYP3A4CYP2D6
SCHEMBL10112493 0.93 PTGER4 (0.38) KDM4EMAPTCYP1A2CYP3A4CYP2D6
SCHEMBL10112488 0.91 FOLH1 (0.40) KDM4EMAPTPKMHPGDALOX15
SCHEMBL10112494 0.90 KDM4E (0.41) KDM4EMAPTCYP1A2CYP3A4CYP2D6
SCHEMBL10112621 0.87 KDM4E (0.40) KDM4EMAPTCYP1A2CYP3A4CYP2D6
SCHEMBL10112385 0.87 GABRG2 (0.41) RAB9AGABRG2GABRB3GABRA5GABRA3
SCHEMBL10112618 0.86 ALDH1A1 (0.41) KDM4EMAPTCYP1A2CYP3A4CYP2D6
SCHEMBL10112627 0.86 FOLH1 (0.40) KDM4EMAPTPKMHPGDALOX15
SCHEMBL30998078 0.86 L3MBTL1 (0.41) KDM4EMAPTPTGER4ALDH1A1
SCHEMBL490488 0.86 L3MBTL1 (0.41) KDM4EMAPTPTGER4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 KDM4E 3476/4885MAPT 4092/4885CYP1A2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.